One-year efficacy and safety of a fixed combination of insulin degludec and liraglutide in patients with type 2 diabetes: Results of a 26-week extension to a 26-week main trial

Diabetes, Obesity and Metabolism

Volumn 17, Issue 10, 2015, Pages 965-973

  Gough, S C L ^a   Bode, B W ^b   Woo, V C ^c   Rodbard, H W ^d   Linjawi, S ^e   Zacho, M ^f   Reiter, P D ^f   Buse, J B ^g  

^a CHURCHILL HOSPITAL   (United Kingdom)

^b ATLANTA DIABETES ASSOCIATES   (United States)

^c UNIVERSITY OF MANITOBA   (Canada)

^d Endocrine and Metabolic Consultants   (United States)

^e Coffs Harbour Diabetes Clinic ^*  (Australia)

^f NOVO NORDISK A S   (Denmark)

^g UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Diabetes therapy; Hypoglycaemia; Insulin degludec; Liraglutide

Indexed keywords

HEMOGLOBIN A1C; INSULIN DEGLUDEC; INSULIN DEGLUDEC PLUS LIRAGLUTIDE; LIRAGLUTIDE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; LONG ACTING INSULIN; METFORMIN; PIOGLITAZONE;

ADULT; ANALYSIS OF COVARIANCE; ARTICLE; BODY MASS; BODY WEIGHT; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; DIARRHEA; DISEASE DURATION; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEADACHE; HEMOGLOBIN BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREATITIS; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; TREATMENT DURATION; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; VOMITING; AGED; BLOOD; CHEMICALLY INDUCED; CLINICAL TRIAL; COMBINATION DRUG THERAPY; DIABETES MELLITUS, TYPE 2; DIET RESTRICTION; DOSE RESPONSE; DRUG EFFECTS; HYPOGLYCEMIA; MIDDLE AGED; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; WEIGHT REDUCTION;

AGED; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FASTING; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN, LONG-ACTING; LIRAGLUTIDE; MALE; METFORMIN; MIDDLE AGED; THIAZOLIDINEDIONES; WEIGHT LOSS;

EID: 84942296569     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12498     Document Type: Article

References (10)

1. van Can J, Sloth B, Jensen CB, Flint A, Blaak EE, Saris WH. Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults. Int J Obes (Lond) 2014; 38: 784-793.
2. Eng C, Kramer CK, Zinman B, Retnakaran R. Glucagon-like peptide-1 receptor agonist and basal insulin combination treatment for the management of type 2 diabetes: a systematic review and meta-analysis. Lancet 2014; 384: 2228-2234.
3. Goldenberg R. Insulin plus incretin agent combination therapy in type 2 diabetes: a systematic review. Curr Med Res Opin 2014; 30: 431-445.
4. Strain WD, Blüher M, Paldánius P. Clinical inertia in individualising care for diabetes: is there time to do more in type 2 diabetes? Diabetes Ther 2014; 5: 347-354.
5. Gough SC, Bode B, Woo V etal. Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetes. Lancet Diabetes Endocrinol 2014; 2: 885-893.
6. Holst JJ, Buse J, Gough SCL etal. A novel fixed-ratio combination of insulin degludec and liraglutide improves postprandial glycaemic control in patients with type 2 diabetes: results from a standardised meal test. Diabetologia 2013; 56: S359.
7. Buse JB, Gough SCL, Rodbard HW etal. Postprandial glycaemic control following a fixed-ratio combination of insulin degludec and liraglutide compared to each component individually in patients with type 2 diabetes. Diabetologia 2013; 56: S417.
8. Altman DG. Practical Statistics for Medical Research. Boca Raton: Chapman & Hall/CRC, 1990.
9. Vora J, Bain SC, Damci T etal. Incretin-based therapy in combination with basal insulin: a promising tactic for the treatment of type 2 diabetes. Diabetes Metab 2013; 39: 6-15.
10. Balena R, Hensley IE, Miller S, Barnett AH. Combination therapy with GLP-1 receptor agonists and basal insulin: a systematic review of the literature. Diabetes Obes Metab 2013; 15: 485-502.